The core challenge in AML therapy lies in the cancer cells’ capacity to evade programmed cell death, or apoptosis, a process that is tightly regulated by a family of proteins known as BCL-2. In normal physiology, BCL-2 family proteins orchestrate the intrinsic apoptotic pathway, balancing pro-apoptotic and anti-apoptotic signals to maintain cellular homeostasis. Leukemic cells subvert this system by overexpressing pro-survival BCL-2 proteins, thereby evading chemotherapy-induced apoptosis and perpetuating malignancy. BH3 mimetics act by simulating the BH3 domain—a critical pro-apoptotic motif—enabling these compounds to selectively inhibit anti-apoptotic BCL-2 family proteins and restore apoptosis in malignant cells.

Among BH3 mimetics, venetoclax has emerged as the most clinically successful agent. This selective BCL-2 inhibitor has demonstrated remarkable efficacy in clinical trials, especially when combined with hypomethylating agents or low-dose cytarabine. These combinations have been shown to significantly enhance remission rates and prolong survival in AML patients, particularly in older individuals or those unfit for intensive chemotherapy—a patient population historically lacking viable therapeutic options. The US Food and Drug Administration (FDA) has accordingly approved these regimens, marking a pivotal advancement in AML management.

Assistant Professor Alan Prem Kumar, a leading voice in pharmacology at NUS Medicine, co-led the review alongside Assistant Professor Courtney DiNardo from the University of Texas MD Anderson Cancer Center. Reflecting on the clinical impact, Asst Prof Kumar emphasizes that venetoclax has “transformed the treatment landscape” by providing first-time access to effective therapy for frail AML patients. This breakthrough represents a paradigm shift away from the traditional, often intolerable chemotherapy regimens towards more targeted, tolerable interventions.

The review, published in Nature Reviews Clinical Oncology, synthesizes findings from over a thousand peer-reviewed articles, with a detailed focus on 236 rigorously selected studies. This exhaustive assessment maps the molecular underpinnings of BH3 mimetic function, elucidates mechanisms of drug resistance, evaluates clinical outcomes, and explores technological advances such as BH3 profiling and mitochondrial profiling. These profiling techniques allow for precise identification of the apoptotic dependencies of individual AML cells, enabling clinicians to predict drug sensitivity and tailor therapies accordingly.

Crucially, BH3 mimetics have demonstrated the ability not only to target proliferating leukemic cells but also to eradicate quiescent, non-dividing populations harboring complex genetic aberrations. This capability is significant as these dormant cells often contribute to relapse and disease persistence. However, while venetoclax heralds an era of improved outcomes, resistance remains a formidable obstacle. AML cells frequently adapt by shifting survival reliance to alternate anti-apoptotic proteins such as MCL-1 or BCL-xL, or by acquiring mutations in adverse prognostic genes including TP53, KRAS, and FLT3.

Donavan Jia Jie Tan, a first-year medical student and study co-author, underscores this therapeutic challenge, noting that cancer cells’ adaptability forces continuous innovation in treatment strategies. By integrating multiple targeted agents, combination regimens, or advanced drug delivery technologies that concurrently disrupt diverse anti-apoptotic pathways, researchers hope to mitigate resistance and enhance the durability of remissions.

This personalized treatment approach is further bolstered by the advent of BH3 and mitochondrial profiling, which Dr Lam Hiu Yan highlights as powerful tools for aligning therapeutic strategy with tumour biology. These methods facilitate the identification of patients most likely to benefit from venetoclax versus those who may require alternative BH3 mimetics targeting MCL-1 or BCL-xL, thus refining clinical decision-making and minimizing unwarranted toxicity.

Looking ahead, Asst Prof Kumar posits that the future of AML therapy hinges on the precision personalization of treatment regimens. Moving beyond a one-size-fits-all paradigm, tailoring interventions to the molecular and cellular characteristics of each patient’s leukemia will optimize efficacy and improve quality of life. This bespoke therapeutic model signals a shift towards more intelligent, biology-driven oncology care.

Independent expert Professor Chng Wee Joo of NUS Medicine, unaffiliated with the study, affirms the transformative impact of venetoclax-based therapies, especially in older adults and medically complex patients. He highlights the dramatic improvements in remission and survival that would have been unimaginable merely a decade ago. Prof Chng identifies next steps in research aimed at enhancing treatment precision, broadening accessibility, and ultimately converting AML from a once invariably fatal disease to a manageable chronic condition.

Current clinical trials are actively examining venetoclax in combination with groundbreaking agents including FLT3 inhibitors and CD47-targeting antibodies, expanding the scope of effective treatment to a wider cohort of AML patients. Parallel development pipelines are pursuing BH3 mimetics directed against MCL-1 and BCL-xL, leveraging advances in medicinal chemistry and structural biology to create novel inhibitors with improved selectivity and potency.

Taken together, this landmark review from NUS Medicine not only encapsulates the profound clinical advances ushered in by BH3 mimetics in AML but also delineates critical scientific and therapeutic challenges ahead. Through multi-disciplinary collaboration and continued innovation, researchers are poised to extend the benefits of these promising agents, paving the way for a new era where acute myeloid leukaemia becomes a disease defined not by its lethality but by the hope of durable remission and long-term survival.

Subject of Research: Acute Myeloid Leukaemia treatment using BH3 mimetics
Article Title: Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia
News Publication Date: 1-Sep-2025
Web References: https://www.nature.com/articles/s41571-025-01068-0
References: DOI 10.1038/s41571-025-01068-0
Image Credits: NUS Medicine
Keywords: Leukemia, Cancer, Myeloid leukemia, Oncology, Tumor regression, Tumor growth, Cancer risk, Blood cancer, Cell apoptosis

Published in the esteemed journal Blood Cancer Discovery, this large-scale study represents the most comprehensive exploration to date focusing on patients receiving combination therapy involving venetoclax and hypomethylating agents (HMAs). By analyzing clinical and molecular data drawn from 678 AML patients, the research team has delineated how specific genetic aberrations in tandem with the developmental state of AML cells collaboratively dictate treatment responsiveness, unraveling complexities previously obscured in standard therapeutic paradigms.

Venetoclax, a potent inhibitor of the anti-apoptotic protein BCL-2, has emerged as a frontline therapeutic agent when combined with HMAs for newly diagnosed AML cases, especially in older adults with poor tolerance for intensive chemotherapy. Despite its promising clinical benefits and improved survival rates, a significant subset of patients exhibits primary resistance or experience disease relapse, hinting at underlying biological heterogeneity that impacts drug efficacy but remained poorly understood until now.

Dr. Daniel Pollyea, professor of medicine at the CU School of Medicine and lead investigator, emphasizes that the clinical heterogeneity seen in AML response patterns stems not only from genetic mutations but also from the cellular differentiation status of the leukemia. "Our study reveals that patient responses are tightly linked to both the mutational landscape and the maturation stage of leukemia cells present at diagnosis," Pollyea explains. This dual-factor model provides a more robust framework for risk stratification than previous mutation-centric approaches.

Critically, the team uncovered that patients with monocytic AML subtypes—characterized by more differentiated leukemic cells—demonstrated markedly poorer outcomes when lacking the favorable NPM1 mutation. These patients were also enriched for additional mutations such as KRAS, a gene frequently implicated in oncogenic signaling and chemoresistance. This constellation of molecular features underscores a distinct biological subset of AML with innate resistance pathways, challenging conventional treatment regimens.

Such findings carry profound clinical implications because they shed light on the ‘escape mechanisms’ leukemic cells deploy to circumvent venetoclax action. The maturation state of monocytic cells appears to enable alternative survival signaling routes, which effectively neutralize the drug’s pro-apoptotic intent. By integrating mutational profiling with cell differentiation markers, clinicians can now better predict which patients harbor such resistant clones and may require alternative or adjunctive therapies.

Historically, AML treatment strategies emphasized genetic abnormalities or cellular phenotypes independently, but this study’s integrative analysis approach reveals a synergistic effect, offering a more nuanced comprehension of therapeutic resistance. "It’s akin to unveiling a back door that cancer cells exploit to dodge treatment," notes Pollyea, highlighting the potential to develop novel agents or combination therapies designed to block these alternative pathways and improve remission durability.

This research not only refines prognostic models but also heralds a tangible shift toward personalized medicine in AML. Utilizing comprehensive molecular and phenotypic data at the point of diagnosis, healthcare providers can now better tailor therapeutic regimens to individual patients’ disease biology, enhancing the likelihood of response and reducing unnecessary exposure to ineffective treatments.

Further collaborative efforts are underway to enlarge the patient dataset and validate the predictive power of this combined model in prospective clinical trials. Pollyea and his colleagues envision forthcoming studies that will employ this knowledge to dynamically guide treatment decisions in real time, potentially transforming therapeutic outcomes in AML—a historically challenging and lethal cancer.

Institutions worldwide contributed to this collaborative effort, including the Knight Cancer Institute at Oregon Health and Science University, multiple French cancer centers such as Hôpital Lyon Sud and CHU Clermont-Ferrand, as well as the Lineberger Comprehensive Cancer Center at the University of North Carolina. Their collective expertise and pooled data resources were instrumental in identifying subtle yet critical biological distinctions within AML patient populations.

The University of Colorado Anschutz Medical Campus, home to the Cancer Center and a nexus of innovative research, continues to cement its role at the vanguard of hematological oncology advances. With robust funding exceeding $900 million annually, including public and philanthropic sources, the campus supports pioneering research endeavors aimed at confronting cancers like AML through cutting-edge science and multidisciplinary collaboration.

This study’s revelations mark an important step forward in decoding the biological variability that governs AML treatment success and failure, fostering hope for more effective, targeted interventions. As Dr. Pollyea articulates, approaching leukemia treatment with nuanced molecular precision not only improves individual patient journey but also pushes the entire field closer to enduring cures for this devastating disease.

Subject of Research: Acute Myeloid Leukemia (AML) treatment response variability based on genetic mutations and leukemia cell maturity.

Article Title: Understanding the Biological Drivers of Venetoclax Resistance in AML: Integrative Insights into Genetic and Cellular Determinants

News Publication Date: June 2024

Web References:

• University of Colorado Cancer Center: https://medschool.cuanschutz.edu/colorado-cancer-center
• Blood Cancer Discovery article: https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0256

Keywords: Acute Myeloid Leukemia, Venetoclax, Hypomethylating Agents, AML Treatment Resistance, NPM1 Mutation, KRAS Mutation, Cancer Cell Differentiation, Personalized Medicine, Hematologic Oncology, Genetic Biomarkers